Physician profile
Mark A Ringold
NPI 1588621023
$3,918.69
in general payments reported to CMS, 2019-2025
30 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $494 · 2021: $414 · 2022: $487 · 2023: $515 · 2024: $604 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.19 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $649.57 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $433.86 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $417.57 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Ardelyx, INC. | $183.86 | 2023-2025 | Ibsrela |
| Celgene Corporation | $130.74 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $125.56 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $117.07 | 2024-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $112.43 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $111.12 | 2019-2021 | |
| Genzyme Corporation | $86.06 | 2022-2023 | |
| Pfizer INC. | $79.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $76.05 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $74.89 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $68.91 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $66.70 | 2025 | Vegzelma |
| Lilly USA, LLC | $60.27 | 2025 | Omvoh |
| Ucb, INC. | $44.12 | 2019-2020 | |
| Gilead Sciences, INC. | $30.63 | 2021 | |
| Horizon Therapeutics Plc | $28.26 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $27.55 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $25.59 | 2020-2021 | |
| Braintree Laboratories, INC. | $21.14 | 2019 | |
| Madrigal Pharmaceuticals | $19.94 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $17.64 | 2021 | |
| Shire North American Group INC | $17.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.45 | 2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $14.15 | 2023 | Rebyota |
| Shionogi INC | $10.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ringold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.